CION Ameerpet
Understanding Your Report · Reviewed by CION Oncologists · NABH Accredited
Uterine Sarcoma — A Different Disease in the Same Organ
Almost everything written about “uterine cancer” describes endometrial carcinoma, which starts in the lining of the womb. Uterine sarcoma starts somewhere else entirely — in the muscle of the uterine wall, or in the connective tissue that supports the lining. Different tissue, different behaviour, different symptoms, a different staging system and different treatment. It is uncommon, which is why it gets so little attention, and it is worth understanding as its own disease rather than as a variant of the common one. If you have been given this diagnosis, most of what you have already read probably does not apply to you.
- It arises from muscle or connective tissue — not from the lining, which is where carcinoma starts
- It often presents as a mass, not bleeding — a rapidly enlarging uterus, pain or pressure
- A biopsy of the lining usually misses it — because it is not growing in the cavity
- Carcinosarcoma is not one of these — despite the name — it is classified as a carcinoma
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Sarcoma Compared With Endometrial Carcinoma
The differences run through everything — where it starts, how it announces itself, how it is found, and how it is treated.
| Endometrial carcinoma | Uterine sarcoma | |
|---|---|---|
| Tissue of origin | The endometrium — the epithelial lining of the cavity. | The muscle of the uterine wall, or the connective tissue supporting the lining. |
| How common | The great majority of uterine cancers. | Uncommon — a small proportion of uterine malignancies. |
| Typical presentation | Abnormal bleeding, particularly after the menopause. | Frequently a rapidly enlarging uterus, pelvic pain or pressure. Bleeding may occur but is less consistently the first sign. |
| How it is diagnosed | Endometrial biopsy, which samples the lining directly. | Often not by biopsy at all, because it is not growing in the cavity. Frequently diagnosed on the specimen after surgery. |
| Oestrogen-driven? | The common type is. Weight and anovulation are the main risk factors. | Generally not, though low-grade endometrial stromal sarcoma often expresses hormone receptors. |
| Staging system | FIGO staging for endometrial carcinoma. | A separate FIGO system for uterine sarcomas, based largely on tumour size and extent. |
| Treatment | Surgery, with radiation or drug treatment depending on risk. | Surgery with intact removal, and drug treatment approaches drawn from sarcoma practice rather than from endometrial carcinoma. |
The name that causes most confusion: carcinosarcoma contains both carcinoma and sarcoma-like components and was once classified as a sarcoma. It is now understood to be a carcinoma that has changed appearance, and it is staged and treated as an aggressive endometrial carcinoma rather than as a sarcoma. If your report says carcinosarcoma, this page is not the one you need — see uterine carcinosarcoma.
Did You Know? There is a real and under-communicated risk in fibroid surgery that follows directly from how sarcoma behaves. Uterine leiomyosarcoma can be indistinguishable from a benign fibroid on imaging, so a small number of women having surgery for presumed fibroids turn out to have a sarcoma. If the uterus is removed by morcellation — cut into pieces to bring it out through small keyhole incisions — an unsuspected sarcoma can be scattered through the abdominal cavity, converting contained disease into disseminated disease. This is why intact removal is recommended wherever sarcoma is a possibility, and why the question deserves an explicit conversation before minimally invasive fibroid surgery, particularly after the menopause. Sources: World Health Organization classification of tumours of female reproductive organs; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; FIGO staging for uterine sarcomas; ESGO–ESTRO–ESP guidance on uterine sarcomas.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
The Main Subtypes
They differ enough that the subtype largely determines the treatment, so it is worth knowing which one your report names.
- Uterine leiomyosarcoma. Arises from the smooth muscle of the uterine wall — the same tissue that produces benign fibroids, which is precisely why the two can be confused. The commonest uterine sarcoma and an aggressive one. See uterine leiomyosarcoma.
- Low-grade endometrial stromal sarcoma. Arises from the connective tissue supporting the lining. Grows slowly, frequently expresses hormone receptors, and can often be controlled with hormone treatment — a considerably more favourable disease than the others here, though it can recur many years later.
- High-grade endometrial stromal sarcoma. From the same tissue but behaving aggressively, and managed quite differently from the low-grade form. The distinction between the two matters a great deal and rests on pathology.
- Undifferentiated uterine sarcoma. A tumour too poorly differentiated to be assigned to the categories above. Uncommon and aggressive.
Because these are uncommon tumours and the subtypes are managed so differently, pathology review by someone who sees sarcomas regularly is worth asking about — the distinction between a cellular fibroid and a leiomyosarcoma, or between low- and high-grade stromal sarcoma, is not always straightforward. See also our sarcoma pages.
Diagnosed With a Uterine Sarcoma?
These are uncommon and the subtype decides everything. Bring the pathology and we will review it as a team.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Uncommon Tumours Benefit Most From Experienced Eyes
The subtype determines the treatment, and the subtype is a pathology judgement worth having reviewed.
How It Is Usually Found
This is where uterine sarcoma differs most sharply from endometrial carcinoma, and where the practical consequences are greatest.
Endometrial carcinoma grows in the cavity and bleeds, so a biopsy of the lining finds it. Sarcoma grows within the wall of the uterus, where a biopsy sampling the cavity does not reach.
- A biopsy of the lining can be entirely normal. A reassuring endometrial biopsy does not exclude a sarcoma, because the sampler was never in contact with it. This is a genuine limitation rather than a failure of the test.
- Imaging raises suspicion but rarely settles it. MRI can show features that suggest a sarcoma rather than a fibroid — rapid growth, unusual appearance, particular patterns on specialised sequences — but no scan reliably distinguishes them. See MRI.
- Many are diagnosed after surgery. A woman has a hysterectomy or fibroid removal for what everyone believes is benign disease, and the pathologist identifies a sarcoma on the specimen. This is a common route to diagnosis and it is nobody’s error.
- Which is why the morcellation question matters. If keyhole surgery for presumed fibroids involves cutting the tissue up to remove it, an unsuspected sarcoma can be spread through the abdomen. Intact removal avoids that, and the trade-off deserves an explicit conversation beforehand.
The features that should raise suspicion before surgery: a uterine mass growing rapidly, particularly after the menopause when fibroids should be shrinking; new pelvic pain with a known fibroid; and an unusual appearance on imaging. None is diagnostic; all are reasons to discuss the surgical approach.
Want the Pathology Reviewed?
With uncommon tumours the subtype decides the treatment, and the subtype is a judgement worth confirming. The opinion is free.
What Treatment Involves
Drawn from sarcoma practice rather than from endometrial carcinoma practice, which is why a woman treated for a sarcoma may find her plan looks nothing like what she has read about womb cancer.
Surgery, with the uterus removed intact
The mainstay of treatment, and the priority is removing the tumour whole rather than through the smallest possible incision. Morcellation is avoided wherever sarcoma is suspected or confirmed. Whether the ovaries are removed depends on the subtype and on menopausal status — for low-grade endometrial stromal sarcoma, which is often hormone-driven, removing them has a therapeutic rationale that does not apply to leiomyosarcoma.
Lymph node surgery is usually not routine
A meaningful difference from endometrial carcinoma. These tumours tend to spread through the bloodstream rather than via lymphatics, so extensive node dissection adds risk without adding much information in most cases. If you have read about sentinel node mapping in endometrial cancer and wondered why it has not been mentioned, that is the reason.
Drug treatment follows sarcoma protocols
The regimens used in uterine sarcoma come from soft tissue sarcoma practice, not from endometrial carcinoma. This is one reason care benefits from a team that treats sarcomas. For low-grade endometrial stromal sarcoma specifically, hormone treatment is often the mainstay and can control disease for long periods with limited toxicity.
Radiation has a more limited role
Used selectively rather than routinely — for local control in particular situations, or to relieve symptoms. It does not occupy the central position it holds in the adjuvant treatment of endometrial carcinoma, and its absence from your plan is not an omission.
Why Rare Tumours Need a Tumour Board
A disease seen rarely is one where a second reading and a team discussion earn the most.
Slides reviewed, not just the summary line
Tumour board for every diagnosis
Named MCh surgical oncologists
One place for the whole pathway
Second opinions welcomed, not resented
Decisions for healing, not billing
Take The Next Step
Most of What You Have Read Probably Does Not Apply
Sarcoma is its own disease. Let us go through what actually applies to yours.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Uterine Sarcoma — Frequently Asked Questions
How is uterine sarcoma different from endometrial cancer?
They arise from completely different tissues in the same organ. Endometrial carcinoma starts in the endometrium — the epithelial lining of the uterine cavity — and is by far the commoner disease. Uterine sarcoma starts in the mesenchymal tissue: the smooth muscle of the uterine wall in the case of leiomyosarcoma, or the connective tissue supporting the lining in the case of endometrial stromal sarcoma. That difference runs through everything. Sarcoma often presents as a rapidly enlarging uterine mass rather than with bleeding, is frequently missed by an endometrial biopsy because it is not growing in the cavity, uses a separate staging system, and is treated with approaches drawn from sarcoma practice.
Can a normal endometrial biopsy rule out a sarcoma?
No, and this is an important limitation to understand. An endometrial biopsy samples the lining of the uterine cavity, which is exactly where endometrial carcinoma grows. A sarcoma arising within the muscle of the uterine wall may never come into contact with the sampling device, so the biopsy can be entirely normal while a sarcoma is present. This is a genuine limitation of the test rather than a failure of technique. Imaging, particularly MRI, can raise suspicion through features such as rapid growth or unusual appearance, but no scan reliably distinguishes a sarcoma from a benign fibroid. Many are diagnosed only on the specimen after surgery.
Is carcinosarcoma a type of uterine sarcoma?
No, despite the name — and this causes real confusion. Carcinosarcoma contains both carcinoma and sarcoma-like components and was historically classified as a uterine sarcoma. It is now understood to be a carcinoma in which some cells have taken on a sarcoma-like appearance, and it is classified, staged and treated as an aggressive endometrial carcinoma rather than as a true sarcoma. If your pathology report says carcinosarcoma, the relevant material is about high-grade endometrial carcinoma, not about leiomyosarcoma or endometrial stromal sarcoma. The distinction genuinely changes which treatment protocols apply.
What is morcellation and why does it matter?
Morcellation is cutting tissue into smaller pieces so it can be removed through the small incisions used in keyhole surgery. It matters because uterine leiomyosarcoma can be indistinguishable from a benign fibroid on imaging, so a small number of women having minimally invasive surgery for presumed fibroids turn out to have a sarcoma. If the tissue has been morcellated, malignant cells can be scattered through the abdominal cavity, converting disease contained within the uterus into disseminated disease and worsening the outlook. Intact removal is therefore recommended wherever sarcoma is a possibility, and the trade-off deserves explicit discussion before surgery, particularly after the menopause.
Does the subtype of sarcoma change the treatment?
Considerably, which is why it is worth knowing exactly which one your report names. Low-grade endometrial stromal sarcoma grows slowly, frequently expresses hormone receptors, and can often be controlled with hormone treatment for long periods with limited toxicity — a substantially more favourable disease than the others, although it can recur many years later. High-grade endometrial stromal sarcoma arises from the same tissue but behaves aggressively and is managed quite differently. Leiomyosarcoma is treated with approaches drawn from soft tissue sarcoma practice. Because these tumours are uncommon and the distinctions are not always straightforward, pathology review is worth asking about.
Medical disclaimer: This page explains uterine sarcoma and how it differs from endometrial carcinoma, and is reviewed by a CION oncologist, following the World Health Organization classification, FIGO staging for uterine sarcomas, and current NCCN guidance. These are uncommon tumours whose management depends heavily on subtype. It is general health information rather than advice about your own case, and treatment decisions should be made with a team experienced in sarcoma.